AB023. Early diagnosis and treatment lead to improve survival of glioblastoma patients
Abstract

AB023. Early diagnosis and treatment lead to improve survival of glioblastoma patients

Yoshitaka Narita, Daisuke Kawauchi, Makoto Ohno, Masamichi Takahashi, Shunsuke Yanagisawa, Takaki Omura, Yasuji Miyakita

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan

Correspondence to: Yoshitaka Narita, MD, PhD. Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Email: yonarita@ncc.go.jp.

Background: Glioblastoma (GBM) is one of the worst prognostic cancers and one of the reasons is that GBM patients rapidly deteriorated and half of them had a Karnofsky performance status (KPS) with 70 or less at the initial presentation. We discuss the significance of early diagnosis and treatment to the clinical outcomes of GBM patients.

Methods: Data of IDH-wildtype GBM patients treated at our institution between 2010 and 2019 were retrospectively reviewed. Patients were classified into early or late diagnosis groups with a threshold of 14 days from initial symptoms. Also, patients were divided into early, intermediate, and late surgery groups with thresholds of 21 and 35 days. Patients were also divided into two groups: neurosurgeon and non-neurosurgeon groups, based on the primary doctor whom patients sought for an initial evaluation. Representative symptoms and patient prognosis were examined.

Results: Of 153 patients, 72 and 81 were classified into the early and late diagnosis groups. The proportion of patients with preoperative KPS scores ≥90 was 48.6% and 29.6% in the early and late diagnosis groups (P=0.01). Median overall survival was significantly longer in the early surgery group (n=43) than in the late surgery group (n=86) (28.4 vs. 18.7 months, P=0.006). The neurosurgeon group exhibited a significantly shorter duration from the first hospital visit to the first surgery than the non-neurosurgeon group (18 vs. 29 days, P<0.001). Furthermore, the overall survival of the neurosurgeon group was significantly more prolonged than that of the non-neurosurgeon group (22.9 vs. 14.0 months, P=0.04).

Conclusions: Early diagnosis and surgery within 3 weeks from the initial symptoms are associated with improved patient survival. Early GBM treatment will be beneficial for patients with GBM. A short duration from the first hospital visit to the first surgery is essential in enhancing GBM patient prognosis.

Keywords: Glioblastoma (GBM); early treatment; surgery; seizure

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cco.amegroups.com/article/view/10.21037/cco-24-ab023/coif). Y.N. reported grants from Ono Pharma, Sumitomo Pharma, Eisai, Daiichi-Sankyo and Ohara. Y.N. also reported personal fees from Ono Pharma, Sumitomo Pharma, Eisai, Daiichi-Sankyo, Taiho, Chugai and Novocure. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the national ethics board of NCC2013-042 and individual consent for this retrospective analysis was waived.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

Cite this abstract as: Narita Y, Kawauchi D, Ohno M, Takahashi M, Yanagisawa S, Omura T, Miyakita Y. AB023. Early diagnosis and treatment lead to improve survival of glioblastoma patients. Chin Clin Oncol 2024;13(Suppl 1):AB023. doi: 10.21037/cco-24-ab023

Article Options

Download Citation

Share